Patents by Inventor Bruce L. Levine

Bruce L. Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells
    Publication number: 20150342994
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 3, 2015
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE
    Publication number: 20150290244
    Abstract: The present invention provides compositions and methods for inducing tolerance in a human. The invention includes administering a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 15, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Methods for treatment of cancer
    Patent number: 9101584
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 9102760
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 9102761
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Toxicity Management for Anti-Tumor Activity of CARs
    Publication number: 20150202286
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 23, 2015
    Applicant: The Children's Hospital of Philadelphai
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Methods for Assessing the Suitability of Transduced T Cells for Administration
    Publication number: 20150190428
    Abstract: The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 9, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Compositions and Methods for Regulating CAR T Cells
    Publication number: 20150140019
    Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
    Type: Application
    Filed: July 12, 2013
    Publication date: May 21, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Methods for Treatment of Cancer
    Publication number: 20150118202
    Abstract: The present invention provides compositions and methods for treating cancer in a human.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 30, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150099299
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150093822
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 8975071
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150050729
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 19, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Methods for treatment of cancer
    Patent number: 8916381
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 23, 2014
    Assignee: The Trustees of the University of Pennyslvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Methods for Treatment of Cancer
    Publication number: 20140370017
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 18, 2014
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 8911993
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: December 16, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Methods for treatment of cancer
    Patent number: 8906682
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer
    Publication number: 20140106449
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 16, 2013
    Publication date: April 17, 2014
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Methods for Treatment of Cancer
    Publication number: 20130309258
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 21, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20130288368
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 10, 2013
    Publication date: October 31, 2013
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone